J Cancer Prev.
2021 Mar;26(1):71-82. 10.15430/JCP.2021.26.1.71.
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
- Miller MS
1 - Allen PJ2
- Brown PH3
- Chan AT4
- Clapper ML5
- Dashwood RH6
- Demehri S7
- Disis ML8
- DuBois RN9
- Glynn RJ10
- Kensler TW11
- Khan SA12
- Johnson BD13
- Liby KT14
- Lipkin SM15
- Mallery SR16
- Meuillet EJ17
- Roden RB18
- Schoen RE19
- Sharp ZD20
- Shirwan H21
- Siegfried JM22
- Rao CV23
- You M24
- Vilar E3
- Szabo E25
- Mohammed A1
- Affiliations
-
- 1Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA
- 2Division of Surgical Oncology, Duke Cancer Institute, Durham, NC, USA
- 3Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, MD Anderson Cancer Center, Houston, TX, USA
- 4Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
- 5Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, USA
- 6Center for Epigenetics & Disease Prevention, Institute of Biosciences & Technology, Texas A&M Health Science Center, Houston, TX, USA
- 7Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
- 8Cancer Vaccine Institute, University of Washington School of Medicine, Seattle, WA, USA
- 9Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA
- 10Division of Preventive Medicine, Brigham & Women’s Hospital, Boston, MA, USA
- 11Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- 12Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
- 13Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA
- 14Department of Pharmacology & Toxicology, Michigan State University, East Lansing, Michigan, New York, NY, USA
- 15Division of Gastroenterology and Hepatology, Weill Cornell University, New York, NY, USA
- 16Department of Oral and Maxillofacial Pathology, College of Dentistry, Ohio State University, Columbus, OH, USA
- 17PHusis Therapeutics, San Diego, CA, USA
- 18Department of Pathology, Cancer Prevention and Control Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 19Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 20Department of Molecular Medicine, University of Texas Science Center at San Antonio, San Antonio, TX, USA
- 21Department of Child Health and Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, USA
- 22Department of Pharmacology, Masonic Cancer Center, University of Minnesota School of Medicine, Minneapolis, MN, USA
- 23Medical Oncology Center for Cancer Prevention & Drug Development, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- 24Department of Pharmacology and Toxicology, Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA
- 25Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
- KMID: 2514697
- DOI: http://doi.org/10.15430/JCP.2021.26.1.71
Abstract
- The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Emerging Trends in Cancer Prevention Agent Development
- The Annual Meeting of the Thai Gynecologic Cancer Society 2019: Meeting report
- Therapeutic Factors Recognized by The Patient and The Therapist in Community Meeting
- The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report
- Past, Present, and Future of Academic Conference in Korean Neuropsychiatric Association
